Dataset Information

In vitro and in vivo characterization of the bifunctional ? and ? opioid receptor ligand UFP-505.

ABSTRACT:

Background and purpose

Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have evaluated the mixed ? opioid receptor agonist/ ? opioid receptor antagonist UFP-505 in vitro and in vivo.

Experimental approach

We measured receptor density and function in single ?, ? and ? /? receptor double expression systems. GTP?³⁵ S binding, cAMP formation and arrestin recruitment were measured. Antinociceptive activity was measured in vivo using tail withdrawal and paw pressure tests following acute and chronic treatment. In some experiments, we collected tissues to measure receptor densities.

Key results

UFP-505 bound to ? receptors with full agonist activity and to ? receptors as a low efficacy partial agonist At ?, but not ? receptors, UFP-505 binding recruited arrestin. Unlike morphine, UFP-505 treatment internalized ? receptors and there was some evidence for internalization of ? receptors. Similar data were obtained in a ? /? receptor double expression system. In rats, acute UFP-505 or morphine, injected intrathecally, was antinociceptive. In tissues harvested from these experiments, ? and ? receptor density was decreased after UFP-505 but not morphine treatment, in agreement with in vitro data. Both morphine and UFP-505 induced significant tolerance.

Conclusions and implications

In this study, UFP-505 behaved as a full agonist at ? receptors with variable activity at ? receptors. This bifunctional compound was antinociceptive in rats after intrathecal administration. In this model, dual targeting provided no advantages in terms of tolerance liability.

Linked articles

This article is part of a themed section on Emerging Areas of Opioid Pharmacology. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.14/issuetoc.

SUBMITTER: Dietis N

PROVIDER: S-EPMC6016625 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

In vitro and in vivo characterization of the bifunctional μ and δ opioid receptor ligand UFP-505.

Dietis N N Niwa H H Tose R R McDonald J J Ruggieri V V Filaferro M M Vitale G G Micheli L L Ghelardini C C Salvadori S S Calo G G Guerrini R R Rowbotham D J DJ Lambert D G DG

British journal of pharmacology 20180514 14

<h4>Background and purpose</h4>Targeting more than one opioid receptor type simultaneously may have analgesic advantages in reducing side-effects. We have evaluated the mixed μ opioid receptor agonist/ δ opioid receptor antagonist UFP-505 in vitro and in vivo.<h4>Experimental approach</h4>We measured receptor density and function in single μ, δ and μ /δ receptor double expression systems. GTPγ<sup>35</sup> S binding, cAMP formation and arrestin recruitment were measured. Antinociceptive activity ...[more]

PMID: 29524334

Similar Datasets

Project description:Nelumbo nucifera Geartn., known as sacred lotus, has been used traditionally in South East Asia as a traditional medicine for various CNS disorders including stress, fever, depression, insomnia, and cognitive conditions.To investigate the in vitro cannabinoid and opioid receptor binding affinities, and in vivo behavioral actions of Nelumbo flower extracts and to isolate the potential compounds to treat CNS associated disorders.The white and pink flowers of N. nucifera were extracted with 95% EtOH, followed by acid-base partitioning using CHCl3 to give acidic and basic partitions. These partitions were subjected to Centrifugal Preparative TLC (CPTLC) to yield benzyltetrahydroisoquinoline (BTIQ) alkaloids and long chain fatty acids, identified by physical and spectroscopic methods. In addition, EtOH extracts and partitions were analyzed for chemical markers by UHPLC/MS and GC/MS. In vitro neuropharmacological effects were evaluated by cannabinoid (CB1 and CB2) and opioid [delta (?), kappa (?), and mu (µ)] competitive radioligand binding and GTP?S functional assays. The in vivo behavioral effect was studied through the use of the mouse tetrad assay at 10, 30, 75 and 100mg/kg/ip doses that revealed the effect on locomotion, catalepsy, body temperature, and nociception of acidic and basic CHCl3 partitions, fractions, and compounds.Three aporphines, nuciferine (1), N-nor-nuciferine (2), asimilobine (3), and five BTIQs, armepavine (4), O-methylcoclaurine (5), N-methylcoclaurine (6), coclaurine (7), neferine (10), and a mixture of linoleic and palmitic acids (LA and PA), were identified and evaluated for cannabinoid and opioid receptor displacement activities. Compounds 5-7 showed binding affinities for the ? opioid receptor with equilibrium dissociation constant (Ki) values of 3.5 ± 0.3, 0.9 ± 0.1, 2.2 ± 0.2 ?M, respectively. Compound 10 displayed affinities for ?-and µ- opioid receptors with Ki values of 0.7 ± 0.1 and 1.8 ± 0.2 ?M, respectively, and was determined to be a weak ? agonist by GTP?S functional assay. The mixture of LA and PA (1:1) showed an affinity for ? opioid receptor with a Ki value of 9.2 ± 1.1 ?M. The acidic and basic CHCl3 partitions, compounds 1 and 7, and 5-7 mixture were subjected to the tetrad assay, of which the acidic partition displayed decreased locomotion and increased catalepsy, antinociception, and hypothermia in animal at doses of 75-100 mg/kg/ip, and also showed clonic-tonic seizures upon touch at 100mg/kg.Bioassay-guided isolation revealed compounds 5-7, 10, and the mixture of LA and PA displayed various degrees of opioid receptor radioligand displacement affinities. The in vivo tetrad assay of acidic CHCl3 partition, enriched with aporphines 1 and 2, displayed actions on all four points of behavioral parameters. It can be concluded that the in vivo mild canabimimetic-type effect observed for the CHCl3 partition is likely mediated through other CNS mechanisms since the extracts, partitions, and isolated compounds had no affinity for the in vitro CB1 and CB2 receptors. This work, along with traditional use and the reported bioactivities of the BTIQ alkaloids, suggested further studies on N. nucifera are needed to understand the roles that the extracts and/or individual compounds might contribute to the behavioral effects.